Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Depreciation & Amortization (CF) of $23.5 million for Q1 2026, down 7.48% year-over-year from $25.4 million in Q1 2025, and little changed quarter-over-quarter from $23.5 million in Q4 2025.
Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $23.5 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.48% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $93.9 million (down 11.67% YoY), while the FY2025 annual figure was $95.8 million, down 11.95% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $23.5 million, roughly flat from $23.5 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $44.5 million in Q2 2022, with the low at $23.4 million in Q3 2025.
- The 5-year median for Depreciation & Amortization (CF) is $28.0 million (2023), against an average of $29.2 million.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) surged 34.04% in 2022, then declined 26.07% in 2023.
- Emergent BioSolutions' Depreciation & Amortization (CF) stood at $35.7 million in 2022, then retreated by 17.09% to $29.6 million in 2023, then retreated by 12.16% to $26.0 million in 2024, then retreated by 9.62% to $23.5 million in 2025, then changed by 0.0% to $23.5 million in 2026.
- Business Quant data shows EBS's Depreciation & Amortization (CF) at $23.5 million in Q1 2026, $23.5 million in Q4 2025, and $23.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 24.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.00 Mn |
| Jun 30, 2026 | 24.00 Mn |
| Mar 31, 2026 | 23.50 Mn |
| Mar 31, 2026 | 23.50 Mn |
| Dec 31, 2025 | 23.50 Mn |
| Dec 31, 2025 | 23.50 Mn |
| Sep 30, 2025 | 23.40 Mn |
| Sep 30, 2025 | 23.40 Mn |
| Jun 30, 2025 | 23.50 Mn |
| Jun 30, 2025 | 23.50 Mn |
| Mar 31, 2025 | 25.40 Mn |
| Mar 31, 2025 | 25.40 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Dec 31, 2024 | 26.00 Mn |
| Sep 30, 2024 | 26.40 Mn |
| Sep 30, 2024 | 26.40 Mn |
| Jun 30, 2024 | 28.50 Mn |
| Jun 30, 2024 | 28.50 Mn |
| Mar 31, 2024 | 27.90 Mn |
| Mar 31, 2024 | 27.90 Mn |